PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



Gilead Licenses Remdesivir to Generic Companies For Sale in 127 Countries .pdf


Original filename: Gilead Licenses Remdesivir to Generic Companies For Sale in 127 Countries.pdf
Author: Administrator.AB-202003031417

This PDF 1.7 document has been generated by WPS 文字 / , and has been sent on pdf-archive.com on 06/08/2020 at 05:26, from IP address 103.121.x.x. The current document download page has been viewed 43 times.
File size: 120 KB (3 pages).
Privacy: public file




Download original PDF file









Document preview


Huateng Pharma

https://en.huatengsci.com

Gilead Licenses Remdesivir to
Generic Companies For Sale in
127 Countries
Gilead Sciences, Inc. said it has signed non-exclusive voluntary licensing
agreements with nine generic pharmaceutical manufacturers based in India,
Pakistan and Eygpt to manufacture and distribute COVID-19 therapy remdesivir
to 127 countries.
Remdesivir is considered a key drug in the fight against COVID-19 as a
randomised clinical trial conducted with the drug on 1,063 patients over 60
centres across US, Europe and Asia demonstrated a faster time to clinical
recovery in hospitalised patients as compared to placebo.


The agreements allow the companies – Cipla Ltd.; Dr. Reddy's Laboratories Ltd.;
Eva Pharma; Ferozsons Laboratories; Hetero Labs Ltd.; Jubilant Lifesciences;
Mylan; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. – to
manufacture remdesivir for distribution in 127 countries.
Company

Country

Approval

Price

Cipla

India

Approved

₹4,000 per 100
mg vial

Huateng Pharma

https://en.huatengsci.com

Hetero

India

Approved

₹5,400 per 100
mg vial

Mylan

India

Approved

₹4,800 per 100
mg vial

Dr. Reddy's
Laboratories Ltd.

India

Pending for
approval

N/A

Jubilant
Lifesciences

India

Pending for
approval

N/A

Syngene

India

Pending for
approval

N/A

Zydus Cadila
Healthcare Ltd.

India

Pending for
approval

N/A

Eva Pharma

Egypt

Pending for
approval

N/A

Ferozsons
Laboratories

Pakistan

Pending for
approval

N/A

Table 1: Companies licensed for remdesivir manufacturing
The countries consist of nearly all low-income and lower-middle income
countries, as well as several upper-middle- and high-income countries that face
significant obstacles to healthcare access.
Afghanistan

Botswana

Cuba

Grenada

Lesotho

Myanmar

Seychelles

Timor-Leste

Algeria

British Virgin
Islands

Curacao

Guatemala

Liberia

Namibia

Sierra Leone

Togo

Angola

Burkina Faso

Djibouti

Guinea

Libya

Nauru

Sint Maarten
(Dutch part)

Tonga

Anguilla

Burundi

Dominica

Guinea Bis

Madagascar

Nepal

Solomon
Islands

Trinidad &
Tobago

Antigua &
Barbuda

Cambodia

Dominican
Republic

Guyana

Malawi

Nicaragua

Somalia

Tunisia

Armenia

Cameroon

Egypt

Haiti

Maldives

Niger

Aruba

Cape Verde

El Salvador

Honduras

Mali

Nigeria

South Sudan

Turks &
Caicos

Azerbaijan

Cayman
Island

Equatorial
Guinea

India

Marshall
Islands

Pakistan

Sri Lanka

Tuvalu

Eritrea

Indonesia

Mauritania

Palau

St. Kitts and
Nevis

Uganda

Eswatini
(Swaziland)

Jamaica

Mauritius

Panama

St. Lucia

Ukraine

Papua New
Guinea

St. Vincent
and the
Grenadines

Uzbekistan

Philippines

Sudan

Vanuatu

Bahamas, The Central Af R.
Bangladesh

Chad

Barbados

Comoros

Ethiopia

Kazakhstan

Micronesia,
Fed. Sts.

Belarus

Congo DR

Fiji

Kenya

Moldova

South Africa Turkmenistan

Huateng Pharma
Belize
Benin

Congo Rep.

https://en.huatengsci.com
Gabon

Kiribati

Korea, Dem.
Cook Islands Gambia, The People's Rep.
(North Korea)

Bermuda

Costa Rica

Georgia

Bhutan

Cote d’Ivoire

Ghana

Table 2: Countries​

Kyrgyzstan

Mongolia

Rwanda

Suriname

Vietnam

Montserrat

Samoa

Tajikistan

Zambia

Morocco

Sao Tome
and Principe

Tanzania

Zimbabwe

Senegal

Thailand

Lao DR (Laos) Mozambique

permitted distribution by the agreements ​

The regulatory approval status of remdesivir varies by country, and the
distribution of remdesivir within each country is subject to local laws and
regulations.
Under the licensing agreements, the companies have a right to receive a
technology transfer of the Gilead manufacturing process for remdesivir to
enable them to scale up production more quickly.
The licensees also set their own prices for the generic product they produce.
The licenses are royalty-free until the World Health Organization declares the
end of the Public Health Emergency of International Concern regarding
Covid-19, or until a pharmaceutical product other than remdesivir or a
vaccine is approved to treat or prevent Covid-19, whichever is earlier.
Related Articles:
COVID-19 Vaccine Data Raises Hope for Three of Candidates
An Antiviral Drug Favipiravir Was Approved For Treating Against COVID-19
UK Approved The Use Of Remdesivir To Treat Some COVID-19 Patients
Three Remdesivir Trials: One Shows Promise for Treating Coronavirus


Gilead Licenses Remdesivir to Generic Companies For Sale in 127 Countries.pdf - page 1/3
Gilead Licenses Remdesivir to Generic Companies For Sale in 127 Countries.pdf - page 2/3
Gilead Licenses Remdesivir to Generic Companies For Sale in 127 Countries.pdf - page 3/3

Related documents


untitled pdf document 2
untitled pdf document
untitled pdf document 1
the relationship between gs 441524 and remdesivir
untitled pdf document
covid 19 research  remdesivir intermediates for research purpose


Related keywords